A PSMA-targeted theranostic agent for photodynamic therapy.

[1]  M. E. Kenney,et al.  Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen , 2016, Molecular Cancer Therapeutics.

[2]  K. Pienta,et al.  PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges , 2016, Prostate Cancer and Prostatic Disease.

[3]  T. Poeppel,et al.  PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status , 2015, Theranostics.

[4]  R. Hicks,et al.  Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France , 2015, The Journal of Nuclear Medicine.

[5]  M. Pomper,et al.  Prostate-specific membrane antigen as a target for cancer imaging and therapy. , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[6]  Esther Mena,et al.  Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer , 2015, Molecular Imaging and Biology.

[7]  P. Choyke,et al.  Photoimmunotherapy Targeting Prostate-Specific Membrane Antigen: Are Antibody Fragments as Effective as Antibodies? , 2015, The Journal of Nuclear Medicine.

[8]  Martin G Pomper,et al.  Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. , 2012, Bioconjugate chemistry.

[9]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[10]  S. Vallabhajosula,et al.  Small molecule inhibitors of prostate specific membrane antigen (PSMA) for SPECT: Summary of phase I studies in patients with prostate cancer (PCa) , 2012 .

[11]  U. Haberkorn,et al.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  M. Pomper,et al.  2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer , 2011, Clinical Cancer Research.

[13]  Hisataka Kobayashi,et al.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. , 2011, Bioconjugate chemistry.

[14]  Hisataka Kobayashi,et al.  Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules , 2011, Nature Medicine.

[15]  Tiancheng Liu,et al.  Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. , 2010, Cancer letters.

[16]  Bryan Q. Spring,et al.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. , 2010, Chemical reviews.

[17]  Tiancheng Liu,et al.  Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. , 2010, International journal of oncology.

[18]  Martin G Pomper,et al.  A low molecular weight PSMA-based fluorescent imaging agent for cancer. , 2009, Biochemical and biophysical research communications.

[19]  Tiancheng Liu,et al.  In vitro targeted photodynamic therapy with a pyropheophorbide‐a conjugated inhibitor of prostate‐specific membrane antigen , 2009, The Prostate.

[20]  A. Kozikowski,et al.  A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. , 2009, Journal of medicinal chemistry.

[21]  M. Pomper,et al.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. , 2008, Journal of medicinal chemistry.

[22]  B. Wilson,et al.  The physics, biophysics and technology of photodynamic therapy , 2008, Physics in medicine and biology.

[23]  M. Kuimova,et al.  Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosesitizer conjugates suitable for photodynamic therapy , 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[24]  Paul Baas,et al.  Photodynamic therapy in oncology. , 2006, The oncologist.

[25]  P Jack Hoopes,et al.  Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. , 2005, Cancer research.

[26]  P. Thorpe,et al.  Anti‐tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate‐specific membrane antigen , 2004, The Prostate.

[27]  William C. Olson,et al.  The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Shafiullah,et al.  Synthesis and biological activities of phthalocyanine-estradiol conjugates. , 2003, Bioorganic & medicinal chemistry letters.

[29]  S. Mohr,et al.  An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells. , 2002, Bioorganic & medicinal chemistry.

[30]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[31]  M. P. Kirpichnikov,et al.  Targeting Phthalocyanines to Tumor Cells Using Epidermal Growth Factor Conjugates , 1999, Tumor Biology.

[32]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[33]  P. Morlière,et al.  New Trends in Photobiology (Invited Review) The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours , 1991 .

[34]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[35]  Robert J. Lee,et al.  Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation. , 2004, Anticancer research.

[36]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.